Exchange: NASDAQ·Updated 07:31 PM EDT
ACAD logo

ACADAcadia Pharmaceuticals Inc

$25.32
$1.60
(6.75%)
Today
Closed $25.32
$0.07
(0.28%)
After Hours
EarningsAug 5
Mkt Cap$4.34B
Vol7.37M
News
all
press releases
Why Acadia Pharmaceuticals Stock Is Soaring Today
Why Acadia Pharmaceuticals Stock Is Soaring Today...
Yahoo! Finance: News
News Placeholder
More News
News Placeholder
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe
The European Commission will review the recommendation and is expected to issue a final decision in the coming months.
Stocktwits
News Placeholder
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc (NASDAQ: FCEL) up 17.6%, BitVentures Limited (NASDAQ: BVC) up 14.1%, and ACADIA Pharmaceuticals Inc...
Benzinga
News Placeholder
DAYBU (trofinetide) Recommended for Approval in the European Union by CHMP
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU...
Business Wire
News Placeholder
Acadia (ACAD) Down 3.7% Since Last Earnings Report: Can It Rebound?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.
Zacks
News Placeholder
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.
Zacks
News Placeholder
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.
Zacks
News Placeholder
ACADIA Pharmaceuticals (NASDAQ:ACAD) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.02). The company had revenue of $268.10 million for...
MarketBeat
News Placeholder
ACADIA Pharmaceuticals Q1 Earnings Call Highlights
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported first-quarter 2026 total revenue of $268 million, and executives said the company is maintaining its full-year outlook as it advances a pipeline led by remlifanserin in Alzheimer's disease psychosis and trofinetide in Japan. Chief Executive Officer Cath...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.